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Abstract
The use of mechanical homogenization in patient sample preparation for 
COVID-19 diagnostics has proven impactful in the face of the global pandemic 
caused by SARS-CoV-2. Through methods including bead beating and shaker mill 
homogenization novel approaches to viral detection have been developed and 
improvements have been made to existing diagnostic workflows for the improve-
ment of throughput and automation capacity. The application of mechanical 
homogenization techniques has enhanced the sensitivity and methodology for 
many molecular based approaches to COVID-19 detection and from a variety of 
sample types ranging from saliva to nasopharyngeal swabs. Additionally, this tech-
nology has been used to help increase laboratory safety during sample processing 
through efficient viral lysis. Herein, the many benefits of mechanical homogeniza-
tion for COVID-19 detection will be discussed in the context of the many diagnostic 
workflows currently utilizing the technique.
Keywords: PCR, viral diagnostics, viral detection, antigen diagnostics,  
antigen detection, molecular diagnostics, COVID-19, homogenization,  
sample preparation, bead mill, shaker mill, bead beater
1. Introduction
Traditionally the process of mechanical homogenization has been employed in 
the laboratory setting for the disruption of animal or plant tissues in preparation for 
downstream molecular applications [1]. However, in the face of a global pandemic 
this technology has been adapted to increase efficacy and efficiency in viral detec-
tion in a variety of COVID-19 diagnostic workflows [2–4].
As the global community began to respond to the spread of SARS-CoV-2, the 
expansion of public health surveillance programs and community testing protocols 
became critical objectives [5]. However, the need for rapid expansion in testing 
capacity caused a tremendous strain on the supply chains providing the equipment 
and reagents traditionally needed for respiratory virus PCR-based testing [6]. As 
in most cases, necessity drove innovation. Given the large number of research and 
academic laboratories equipped to assist in PCR testing, many groups began to 
offer their assistance in processing patient samples while others began examining 
novel approaches to viral detection which circumvented the supply chain bottle 
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necks. During the development of these novel testing protocols laboratory safety, 
diagnostic assay sensitivity and specificity became top priority [5–7]. In an attempt 
to utilize common laboratory equipment to safely speed up testing efforts, the use 
of mechanical homogenization was proposed to inactivate the SARS-CoV-2 from 
nasopharyngeal swabs as a method of increasing safety during processing [2–4, 8].
In brief, mechanical homogenization is the process of using shearing forces 
applied via mechanical grinding media and rigorous repetitive motion to dissociates 
a given sample [1]. The parameters at which a sample is processed will impact the 
degree to which it is dissociated and the quality of the targeted product for down-
stream applications [1]. In the case of SARS-CoV-2, the goal of mechanical homog-
enization was to disrupt the viral envelope while still maintaining the integrity of 
its RNA [2, 3]. This allowed for a reduction in infective potential in the laboratory 
setting, while preserving the accuracy of polymerase chain reaction (PCR) based 
diagnostic assays [2, 3].
Following the initial application of mechanical homogenization to COVID-19 
swab-based PCR protocols, this technology was adapted to process saliva samples 
for both antigen and PCR detection workflows [2–4]. Through mechanical homog-
enization, high viscosity saliva samples were sufficiently processed to allow for 
automation integration, paving the way for the widespread application of this novel 
methodology [4, 9].
In this chapter we will further explore the applications of homogenization in 
response to the COVID-19 pandemic and the multiple diagnostic methodologies 
this technology has been implemented in and its impact on laboratory safety and 
overall testing efficiency.
2.  Direct-to-PCR testing with shaker mill homogenization of 
nasopharyngeal swabs
During the late spring of 2020, while SARS-CoV-2 was spreading exponentially 
and uncontrollably across the globe, testing for this disease was focused entirely 
on RT-qPCR detection of the virus using US CDC or WHO approved primers [5, 
10]. The traditional method for these types of RT-qPCR tests involved two major 
components. First, the process of virus inactivation and RNA extraction completed 
through a series of chemical reactions that resulted in purified viral RNA from the 
provided patient sample [5, 6, 10]. The extracted RNA was then utilized in the sec-
ond half of this method, amplification and detection [5, 6, 10]. Through RT-qPCR, 
the purified RNA from the patient sample was combined with the preapproved 
primers for attempted amplification of the targeted genes, indicating the presence 
or absence of SARS-CoV-2 depending on the level of amplification seen [5, 6, 10]. 
The RNA amplification was quantified and reported out as a Cq value, with any Cq 
less than 40 qualifying as a COVID-19 positive sample per the US CDC and WHO 
guidelines [10].
The necessity of testing drove up demand for all reagents, machines, and plastics 
utilized in the RT-qPCR testing method, overstressing the supply chain for these 
products [5, 8, 9]. Additionally, the need for cold storage of reagents involved in the 
extraction process and the high price tag on the automated machinery needed to 
complete both the extraction and detection phases of the traditional testing method, 
furthered the gap between resource challenged areas and the industrialized regions 
when it came to COVID-19 testing infrastructure [11, 12]. Areas with the capital 
needed to create multimillion dollar testing facilities were able to do so, improving 
their public health response to the pandemic, while those lacking that investment 
and infrastructure were left with reduced testing capabilities [11]. A critical need 
3
The Utility of Mechanical Homogenization in COVID-19 Diagnostic Workflows
DOI: http://dx.doi.org/10.5772/intechopen.97110
arose for a cost efficient, yet safe and effective testing methodology that could be 
implemented in these resources challenged settings [8, 11].
While the utility of mechanical homogenization in COVID-19 testing was 
already established as an effective adjunct to the extraction process, improving 
sensitivity through efficient viral lysis, this process was expanded upon in an 
attempt to remove the extraction process entirely allowing for direct detection of 
SARS-CoV-2 from lysed patient samples [2, 3]. The direct-to-PCR approach for 
COVID-19 testing arose out of necessity to reduce the use of costly reagents in a 
period where the strain on the supply chain made them difficult to come by [2, 3, 8]. 
Additionally, this proposed method dramatically reduces cost when compared with 
the fully automated extraction machinery [2, 3, 8].
In the direct-to-PCR method for viral detection, shaker mill mechanical 
homogenization was proposed to provide sufficient viral lysis off nasopharyngeal 
swabs to expose adequate amounts of RNA for RT-qPCR detection [2, 3]. This 
method was shown to lyse greater than 95% of virus off a nasopharyngeal swab, 
allowing the resultant lysate to be placed directly into the RT-qPCR reaction as 
denoted in Figure 1 [2, 3].
Through proof-of-concept testing with a close relative of SARS-CoV-2, human 
coronavirus 229E (HCoV-229E), and direct comparison studies between the 
traditional extraction-based method and the direct-to-PCR method, it was shown 
that the two methods had above a 94% agreeability in the detection of positive 
samples [2, 3]. Utilizing the direct-to-PCR method diagrammed in Figure 1, 
shaker mill homogenization was proven to be a viable alternative to the traditional 
extraction-based method for RT-qPCR detection of SARS-CoV-2 off nasopharyn-
geal swabs [2, 3].
In addition to the quality of the matched proven efficacy with the traditional, 
extraction-based methodology, the direct-to-PCR method described utilizing 
mechanical homogenization also reduces the total cost and time per swab processed 
[2, 3, 8]. The traditional model for nasopharyngeal swab viral testing cost $10 - $40 
USD per swab, when taking into account the extraction kits, automation equipment 
for extractions, and the RT-qPCR set up [8]. Compared to $3 - $5 USD per swab 
with the homogenization methodology, given that this workflow does not require 
additional reagents for viral nucleotide extraction and purification, the only reagent 
costs are associated with the final RT-qPCR testing [8]. The homogenization 
equipment utilized in this workflow is sold at a fraction of the cost of the large fully 
automated extraction machinery.
Along with reducing cost per sample the homogenization workflow reduces the 
total processing time per sample from approximately 3 hours to 1 hour and 15 min-
utes [2, 3]. This is accomplished through replacing the extraction and purification 
steps of the traditional workflow with a 30 sec homogenization step preceding 
the RT-qPCR [2, 3]. Further supporting the implementation of this workflow into 
Figure 1. 
The direct-to-PCR viral detection methodology using shaker mill homogenization off nasopharyngeal swabs.
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the COVID-19 testing repertoire to assist in increasing access to cost effective and 
timely viral detection methods that maintain sensitivity and specificity when 
compared to the traditional testing methodologies [8].
3.  PCR detection of COVID-19 from saliva utilizing bead beating 
homogenization
After months of nasopharyngeal swabbing for COVID-19 diagnostic testing, 
there was a push to look for equally sensitive testing methodologies which provided 
a more pleasant patient experience during sample collection [4, 6, 9]. By improving 
the patient experience with testing, the hope was to gain public cooperation with 
viral surveillance efforts [9, 13]. The high concentration of SARS-CoV-2 particles 
found throughout the upper respiratory tract led researchers to begin examining the 
utility of oral swabs or saliva in the current RT-qPCR testing strategies [13, 14].
Saliva samples were shown to have adequate viral loads for reliable RT-qPCR 
detection, however the high viscosity of the samples made them difficult to 
pipette preventing the utilization of the fully automated extraction machin-
ery already in place in many large public health testing facilities [9, 13, 14]. 
Mechanical homogenization in the form of beat beating homogenization was 
introduced to saliva samples to break up the viscous structure and expose the viral 
particles [4, 15]. The beat beating strategy utilized ceramic bead media within a 
2 mL screw capped sample tube and a mechanical homogenizer to apply rigorous 
kinetic energy to the saliva sample for 30 seconds to achieve complete dissociation 
(Figure 2) [4, 15]. It was shown that the kinetic energy transferred from the bead 
beading media homogenized in a sigmoidal pattern was highly effective in dis-
sociating the sample to allow for pipettable lysate that could then be implemented 
into fully automated extraction-based PCR testing workflows [1, 4, 15]. With the 
addition of bead beating homogenization to this workflow, the throughput and 
sensitivity of the assay were dramatically increased [4, 15]. Prior to the imple-
mentation of beat beating homogenization, saliva-based testing demonstrated 
a sensitivity in the mid to low 80% range and throughput was limited to a few 
hundred samples per day via manual processing [4, 15]. Currently, saliva-based 
PCR testing utilizing mechanical homogenization prior to extraction procedures 
demonstrated a 95% sensitivity and 99% specificity, closely matching that of 
nasopharyngeal swab-based testing for COVID-19 [4, 13–15]. Additionally, with 
the capability of full automation integration, throughput of sample processing 
increased from hundreds to thousands of samples per day with the utilization of 
bead beating homogenization equipment [4, 15].
Figure 2. 
The methodology for saliva-based testing utilizing bead beating mechanical homogenization for adequate 
sample dissociation and viral lysis followed by RNA extraction for RT-qPCR viral detection.
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Given the similar sensitivity and specificity for SARS-CoV-2 testing, with the 
improvement in patient experience during sample collection, this method was 
implemented at universities across the state of Georgia as a community surveillance 
program [4, 15]. The difference in patient experience from obtaining a nasopha-
ryngeal swab versus a saliva sample for weekly surveillance measures dramatically 
improved community compliance with testing, validating saliva testing as a viable 
public health surveillance strategy for COVID-19 propagation in a community [4, 
6, 13–15]. Similar entities have now implemented saliva-based testing that utilize 
front-end mechanical homogenization across the world to improve compliance with 
public health testing efforts [4, 6, 15].
4. Viral antigen detection from saliva
The United States’ Food and Drug Administration (FDA) has approved the use of 
antigen testing for the detection of SARS-CoV-2 in the summer of 2020 to increase 
the national testing capacity [6, 16]. Antigen tests are immunoassays that are com-
monly used in the diagnosis of respiratory pathogens such as influenza [17]. Antigen 
test are designed to detect the presence of a specific viral antigen, which is defined 
as a toxin or other foreign substance which induces an immune response [16, 17]. 
Antigen test are currently approved for nasopharyngeal swab specimens however 
studies suggest saliva samples may be just as effective in detecting viral antigens  
[6, 16, 18]. When compared to PCR test, antigen testing is relatively inexpensive, and 
most test results are available in 15 minutes or less. Antigen test in general are less 
sensitive than RT-PCR test as well as other nucleic acid amplification test (NAATs) 
[19]. Alternatively, RT-PCR can amplify and detect minute levels of nucleic acid that 
cannot be cultured which in this case suggest the presence of viral nucleic acids does 
not signify contagiousness [20]. Both antigen and nucleic acid tests are optimal when 
the patient is at their viral load peek [6, 16, 20]. More data is needed to guide the use 
of antigen tests on asymptomatic individuals and to determine if those who were at 
one time diagnosed positive for SARS-CoV-2 remain infectious.
The advantage of antigen testing is its convenience and accessibility in the use 
screening high-risk congregate settings such as primary or secondary educational 
environments, as well as correctional facilities [16, 21]. Repeat testing could quickly 
identify infection, therefore allowing implementation of patient quarantine and 
other preventive measure. However, health care professionals need to understand the 
limitations of antigen testing [19, 20]. Specifically, the testing factors and analytical 
performance characteristics, such as sensitivity, specificity, and accurate positive and 
negative predicted values. The “Holy Grail” for SARS-CoV-2 testing remains to be 
RT-PCR or some form of nucleic acid amplification testing [21]. Nucleic acid testing 
should be used to confirm an antigen test to avoid inconsistent and inaccurate results 
test performance may vary based on specimen choice, quality of specimen, the pres-
ence of transport medium, and the amount of time required for transport [20, 21]. 
Since antigen test are typically less sensitive than NAAT testing, negative results can 
occur while RT-PCR tests may return a positive result [19]. This may occur is speci-
men sample is collected early before symptom onset or late in the infection [19, 20]. 
The specificity of antigen tests is as high as NAAT testing, reducing the likelihood 
of false positives [16, 21]. False positive will still occur, particularly in communities 
where prevalence of infection is low [16, 20, 21]. The CDC recommends testing 
professionals establish infection prevalence for antigen testing based on a rolling 
average, using the positivity rate of their own SARS-CoV-2 testing over the previous 
7–10 days, while considering the clinical and epidemiological context of the person 
or community being tested [6, 16].
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Despite the debated advantages and disadvantages of antigen testing, the 
concept of saliva-based antigen testing for SARS-CoV-2 detection gained traction 
due to the ease of use for the patient and potential for rapid turn around time in 
laboratory processing to support public health efforts. However, as noted in the 
previous section on saliva-based PCR testing, working with such a viscous material 
posed difficulty in automation integration prior to the addition of homogenization 
into the workflow. Antigen testing faced similar difficulties when using saliva for 
large scale testing, the viscous patient samples required further processing prior to 
automation integration.
In an attempt to mitigate variations in saliva viscosities and allow for sample 
integration into high-throughput liquid handler reliant workflows, several protocols 
were developed to dissociate the saliva samples while maintaining intact antigen 
for detection [6, 22]. These protocols recommend various combinations of heating 
and enzyme digestion; heating greater than 60 degrees centigrade for as long as an 
hour or incubating with Proteinase K as an enzymatic digestion [23]. Reports have 
found these techniques to be somewhat effective in permitting antigen detection 
from saliva samples, however inconsistencies have also been scored [18, 20, 23]. 
Heating can denature the viral proteins and RNA, rendering them undetectable, 
and enzymes such as Proteinase K is very costly as well as cause degradation of 
targeted proteins through excessive digestion [20]. Not to mention the suggested 
incubation periods as great as an hour extends the amount of time required to have 
a patients’ result.
Just as with saliva-based PCR testing, homogenization was proposed as a 
method for efficient sample disruption [24]. Viscosity in homogenized saliva 
samples has been shown to be greatly reduced to amounts that are similar to those 
found in water. Allowing for ease in pipetting and increase throughput using 
automation and liquid handlers [15]. The various forces found in homogenization 
are only required for small amounts of processing time, as short as 5 seconds per 
sample without generating any extra heat during the processing, maintaining the 
integrity of the antigens targeted. In contrast to other proposed methods for saliva 
processing in antigen detection, additional enzymes are not required, saving costs 
and without any needed incubation steps, also saving valuable time during testing.
5. Improving laboratory safety with homogenization
During the COVID-19 global pandemic, safety of all individuals involved in the 
care of COVID-19 patients as well as laboratory and clinical staff involved in testing 
for SARS-CoV-2 became a top priority. Given the highly virulent nature of SARS-
CoV-2 and the lack of knowledge and treatments we had available, it was essential 
to neutralize the virus during laboratory testing while preserving the diagnostic 
capacity of all assays [5]. Employing viral neutralization techniques in the diag-
nostic workflow was a critical step in increasing the number of facilities available 
to process COVID-19 patient samples, supporting increased public health testing 
efforts.
Techniques involving thermal inactivation, chemical neutralization or degrada-
tion, enzymatic digestion, and mechanical disruption of samples were all proposed 
as potential solutions to laboratory safety when handling potential COVID-19 
positive patient samples [5, 6]. However, given the global strain on the plastics 
and chemical reagents needed to complete many of these neutralization steps, the 
authors felt it was prudent to examine the potential of mechanical sample dissocia-
tion in the form of homogenization and its effect on virus neutralization [2, 3, 8]. 
Ultimately, it was shown that following 30 seconds of homogenization, 98% of the 
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virus in any given sample was inactivated, while still preserving the genetic material 
for adequate PCR detection [2, 3]. This finding supported expanding the implemen-
tation of homogenization in the COVID-19 diagnostic workflow because it could 
be done both in the laboratory setting, as well as the location of sample collection 
provided the homogenized sample would be properly refrigerated and transferred 
for PCR detection within the next 12 hours [2–4, 15].
The mechanical lysis of the SARS-CoV-2 particles in a potentially infectious 
sample permitted these samples to be processed in a BSL-2 facility, supporting the 
expansion of laboratory testing facilities equipped to process COVID-19 samples 
[2, 3, 8]. Without a proven neutralization step, such as mechanical homogeniza-
tion, all COVID-19 samples would have to be processed in BSL-3 facilities due to 
the potential risk of exposure to infectious virus. While it is still recommended that 
the homogenization procedure occur in a biosafety cabinet within a BSL-2 facil-
ity, the procedure provides sufficient viral lysis to improve safety when handling 
potentially infected patient samples and allows additional laboratories to assist with 
testing in a cost-effective manner [2, 3, 8, 15].
6. Conclusion
Mechanical homogenization has proven its utility in the response to COVID-19 
through shaker mill and bead beating technologies implemented in a variety of 
diagnostic workflows [2–4, 8, 15]. These innovations made possible through effec-
tive and efficient viral lysis of SARS-CoV-2 are proving to improve access, speed, 
and safety while processing patient samples [2–4, 8, 15]. As the global community 
continues to push innovation to combat COVID-19, mechanical homogenization 
should be viewed as one of the many repurposed technologies adapted to assist with 
the response through improving the safety and efficacy of diagnostic testing in a 
cost-effective manner.
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